Orphazyme A/S Operating Income

The latest operating income for ORPHY is $-14M as of June 2024. That compares with $-820M in the prior-year period — up 98.3% year over year. Investors often review this figure alongside Orphazyme A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, ORPHY's operating income moved from $-820M to $-14M — a 98.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Orphazyme A/S's operating scale or balance-sheet position.

A operating income figure of $-14M for ORPHY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ORPHY's operating income ($-14M), review year-over-year change from $-820M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Orphazyme A/S's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.